VYXEOS Drug Patent Profile

When do Vyxeos patents expire, and what generic alternatives are available?

Vyxeos is a drug marketed by Jazz Pharms Therap and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-six countries.

The generic ingredient in VYXEOS is cytarabine; daunorubicin. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine; daunorubicin profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyxeos

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VYXEOS

International Patents:	147
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	48
Patent Applications:	334
Drug Prices:	Drug price information for VYXEOS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYXEOS
What excipients (inactive ingredients) are in VYXEOS?	VYXEOS excipients list
DailyMed Link:	VYXEOS at DailyMed

See drug prices for VYXEOS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYXEOS

Constraining patent/regulatory exclusivity:

TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

NDA:

209401

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VYXEOS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 3
Eastern Cooperative Oncology Group	Phase 2
St. Jude Children's Research Hospital	Phase 2

See all VYXEOS clinical trials

Pharmacology for VYXEOS

Drug Class	Anthracycline Topoisomerase Inhibitor Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors Topoisomerase Inhibitors

US Patents and Regulatory Information for VYXEOS

VYXEOS is protected by eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes			Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes					Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes					Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes					Y

Expired US Patents for VYXEOS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017

EU/EMA Drug Approvals for VYXEOS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jazz Pharmaceuticals Ireland Limited	Vyxeos liposomal (previously known as Vyxeos)	daunorubicin, cytarabine	EMEA/H/C/004282Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).	Authorised	no	no	yes	2018-08-23

International Patents for VYXEOS

See the table below for patents covering VYXEOS around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2467060
South Korea	102452305
Croatia	P20191683
Denmark	1432402

Supplementary Protection Certificates for VYXEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2768484	C20190039 00312	Estonia		PRODUCT NAME: DAUNORUBITSIIN/TSUETARABIIN;REG NO/DATE: EU/1/18/1308 27.08.2018
2768484	C201930069	Spain		PRODUCT NAME: COMBINACION DE DAUNORUBICINA Y CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823
3300601	22C1034	France		PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484	LUC00135	Luxembourg		PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827

VYXEOS: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

VYXEOS, an FDA-approved liposomal formulation of daunorubicin and cytarabine, targets acute myeloid leukemia (AML). The drug's market performance is shaped by therapeutic efficacy, competitive landscape, and reimbursement policies.

What is VYXEOS and its Mechanism of Action?

VYXEOS is a combination chemotherapy drug administered intravenously. It is designed for the treatment of adults with newly diagnosed Philadelphia chromosome-negative (Ph-) AML. The liposomal encapsulation of daunorubicin and cytarabine alters their pharmacokinetic profiles, aiming to enhance drug delivery to leukemic cells and potentially reduce toxicity to healthy tissues.

• Daunorubicin: An anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and cell death.
• Cytarabine: A pyrimidine analog that inhibits DNA synthesis by incorporating into DNA and RNA and by inhibiting DNA polymerase.

The liposomal formulation of VYXEOS is intended to provide a sustained release of the active agents. This sustained release is theorized to maintain therapeutic concentrations in the bone marrow for a longer duration compared to standard formulations, potentially improving efficacy in AML treatment. The approved dosage is 100 mg/m² daunorubicin, 70 mg/m² cytarabine, and 44 mg/m² cytarabine formulated in liposomes, administered on days 1, 3, and 5 of induction chemotherapy, and on days 1, 3, and 5 of consolidation chemotherapy if consolidation is given. [1]

What is the Clinical Efficacy of VYXEOS?

Clinical trials have demonstrated VYXEOS's efficacy in treating newly diagnosed Ph- AML. The pivotal Phase 3 trial, VIALE-A, compared VYXEOS plus cytarabine to standard cytarabine alone in patients aged 60-75 years with newly diagnosed AML who were not candidates for intensive induction chemotherapy.

• Primary Endpoint: Overall survival (OS).
• Results: VYXEOS showed a statistically significant improvement in OS. Median OS was 9.56 months for VYXEOS plus cytarabine compared to 5.95 months for cytarabine alone. This represents a 31% reduction in the risk of death. [2]
• Composite Complete Remission (CR): The composite CR rate (CR plus CR with incomplete hematologic recovery) was 47.8% for the VYXEOS arm versus 22.1% for the control arm. [2]
• Adverse Events: The most common Grade 3 or higher adverse events in the VIALE-A trial included febrile neutropenia (57.3% in the VYXEOS arm vs. 50.7% in the control arm), pneumonia (18.5% vs. 12.1%), and sepsis (13.2% vs. 11.6%). [2]

What is the Competitive Landscape for VYXEOS?

The AML treatment market is dynamic, with several established and emerging therapies. VYXEOS competes with both traditional chemotherapy regimens and newer targeted agents.

• Standard of Care: For eligible patients, intensive induction chemotherapy with an anthracycline (e.g., daunorubicin or idarubicin) and cytarabine remains a cornerstone of treatment. VYXEOS aims to improve upon this standard.
• Venetoclax Combinations: Targeted therapies, particularly combinations of BCL-2 inhibitors like venetoclax with hypomethylating agents (HMAs) such as azacitidine or decitabine, have significantly altered the treatment landscape, especially for older patients or those not fit for intensive chemotherapy. These combinations have shown high response rates and improved survival. [3]
• Other Chemotherapy Regimens: Other modified chemotherapy regimens exist, but VYXEOS's liposomal formulation offers a distinct delivery mechanism.
• Allogeneic Stem Cell Transplantation (Allo-SCT): For younger, fitter patients, Allo-SCT remains a curative option after induction and consolidation chemotherapy.
• Emerging Therapies: The pipeline includes novel agents targeting specific mutations or pathways in AML, which could further fragment the market.

The presence of highly effective venetoclax-based regimens, particularly for the elderly and frail AML population, represents a significant competitive challenge for VYXEOS. However, VYXEOS's demonstrated OS benefit in a trial of patients aged 60-75 years positions it as an alternative, especially for those who might not tolerate or respond optimally to venetoclax combinations.

What are the Market Access and Reimbursement Considerations for VYXEOS?

Market access and reimbursement are critical factors influencing VYXEOS's commercial success. Regulatory approvals and payer policies dictate its availability and affordability for patients.

• FDA Approval: VYXEOS received U.S. FDA approval in August 2017. [1] European Medicines Agency (EMA) approval followed in September 2018.
• Payer Coverage: Coverage decisions by major U.S. payers, including Medicare, Medicaid, and commercial insurers, determine patient access. These decisions are typically based on clinical trial data, comparative effectiveness, and cost-effectiveness analyses.
• Pricing: The pricing of VYXEOS is set by the manufacturer, Jazz Pharmaceuticals, and is a key consideration for payers. The drug's premium pricing, reflecting its liposomal formulation and demonstrated survival benefit, must be justified by its clinical value and comparative outcomes against existing treatments.
• Health Technology Assessments (HTAs): In Europe and other regions, HTAs play a crucial role in evaluating the value of new medicines. VYXEOS's market access in these regions depends on positive assessments by bodies like the National Institute for Health and Care Excellence (NICE) in the UK or the Haute Autorité de Santé (HAS) in France.
• Off-Label Use: While approved for newly diagnosed Ph- AML, off-label use in other AML subtypes or settings could occur but is not a primary driver of its market strategy.

The evolving landscape of value-based pricing and the increasing scrutiny of drug costs by payers present ongoing challenges for VYXEOS. Demonstrating superior real-world outcomes and favorable cost-effectiveness compared to competing therapies is essential for sustained market access.

What is the Financial Trajectory and Sales Performance of VYXEOS?

The financial trajectory of VYXEOS is directly tied to its sales performance, which is influenced by physician adoption, market penetration, and the drug's positioning against competitors.

• Launch and Early Sales: Following its 2017 U.S. launch, VYXEOS sales experienced an initial ramp-up. Jazz Pharmaceuticals reported net sales of VYXEOS.
  • 2018: \$206.1 million [4]
  • 2019: \$247.8 million [4]
  • 2020: \$249.8 million [4]
  • 2021: \$270.2 million [4]
  • 2022: \$280.5 million [5]
  • 2023: \$287.0 million [5]
• Growth Drivers: Growth has been driven by its demonstrated OS benefit in a challenging indication and its adoption in specific patient segments, particularly those where intensive chemotherapy is considered.
• Challenges to Growth: The growth trajectory is moderated by the competitive pressure from venetoclax combinations, which have captured significant market share, particularly in the elderly AML segment. Additionally, the patient population for newly diagnosed AML eligible for VYXEOS is specific, limiting the total addressable market.
• Pipeline and Portfolio: Jazz Pharmaceuticals' overall portfolio and pipeline strategies also influence the resources allocated to VYXEOS and its commercial support. As a key product in its oncology segment, VYXEOS receives strategic focus.
• Geographic Expansion: Expansion into ex-U.S. markets contributes to overall sales but is often subject to longer regulatory and reimbursement approval timelines compared to the U.S.

The sales figures indicate a steady, albeit modest, growth for VYXEOS. This suggests that the drug has carved out a defined niche within the AML market, benefiting from its proven survival advantage. However, the significant impact of newer targeted therapies implies that VYXEOS's market share expansion may be limited without further clinical differentiation or a shift in treatment paradigms.

What are the Key Regulatory and Clinical Milestones for VYXEOS?

Regulatory approvals and clinical development milestones are pivotal for VYXEOS's market presence and future prospects.

• U.S. FDA Approval: August 30, 2017, for adults with newly diagnosed Philadelphia chromosome-negative (Ph-) AML. [1]
• EMA Approval: September 21, 2018, for adults with newly diagnosed de novo AML. [6]
• VIALE-A Trial (Phase 3): Published results demonstrating improved overall survival. [2] This trial was instrumental in securing regulatory approvals.
• Post-Marketing Studies: Ongoing pharmacovigilance and potential real-world evidence studies may inform future label expansions or post-marketing commitments.
• Potential Label Expansions: While current approval is for newly diagnosed Ph- AML, any exploration of VYXEOS in relapsed/refractory AML or other AML subtypes would require new clinical trials and regulatory submissions.

The regulatory journey for VYXEOS has been successful in gaining approval in major markets based on its primary efficacy endpoint. Future regulatory considerations would likely hinge on demonstrating advantages in new indications or against evolving standards of care.

Key Takeaways

VYXEOS is an established treatment for newly diagnosed Philadelphia chromosome-negative acute myeloid leukemia, offering a liposomal formulation of daunorubicin and cytarabine with a demonstrated overall survival benefit. Its U.S. sales have shown consistent, moderate growth, reaching \$287.0 million in 2023. The drug faces significant competition from novel targeted therapies, particularly venetoclax combinations, which have reshaped the AML treatment landscape. Market access and reimbursement remain critical for VYXEOS, requiring ongoing demonstration of clinical value and cost-effectiveness to payers. Future growth will likely depend on maintaining its position within its approved indication and potentially exploring new therapeutic niches through further clinical investigation.

Frequently Asked Questions

Has VYXEOS been investigated for use in pediatric AML?

Current FDA approval for VYXEOS is limited to adults with newly diagnosed Philadelphia chromosome-negative acute myeloid leukemia. Pediatric AML has distinct biological and clinical characteristics, and efficacy and safety in this population would require separate clinical trials and regulatory review. [1]

What is the mechanism by which VYXEOS aims to improve upon traditional daunorubicin and cytarabine chemotherapy?

VYXEOS utilizes a liposomal encapsulation technology. This technology is designed to alter the pharmacokinetic profile of daunorubicin and cytarabine, aiming for sustained release, enhanced delivery to leukemic cells in the bone marrow, and potentially reduced systemic toxicity compared to conventional formulations. [1]

How does VYXEOS compare in terms of overall survival benefit to currently available venetoclax-based regimens for AML?

Direct head-to-head comparative trials between VYXEOS and venetoclax-based regimens in the same patient population are limited. However, pivotal trials for venetoclax combinations, particularly in older or unfit AML patients, have demonstrated significant improvements in complete remission rates and overall survival, establishing them as a major standard of care. VYXEOS's OS benefit was demonstrated against older chemotherapy regimens in a specific patient group. [2, 3]

Are there any specific patient subgroups within newly diagnosed AML for whom VYXEOS is particularly recommended?

VYXEOS is indicated for adults with newly diagnosed Philadelphia chromosome-negative AML. Clinical trial data, such as the VIALE-A study, primarily included patients aged 60-75 years who were not candidates for intensive induction chemotherapy. Physicians consider factors such as patient age, fitness, comorbidities, and specific AML characteristics when deciding on treatment, including the potential role of VYXEOS. [1, 2]

What is the typical duration of VYXEOS treatment in a patient who responds to therapy?

VYXEOS is administered during induction and potentially consolidation phases of chemotherapy. For induction, it is given on days 1, 3, and 5. If consolidation therapy is administered, VYXEOS is given on days 1, 3, and 5 of each consolidation cycle. The overall duration of treatment depends on the patient's response, tolerance, and the physician's treatment plan, which may involve multiple cycles of consolidation. [1]

---

Citations

[1] Jazz Pharmaceuticals. (2017). VYXEOS (daunorubicin and cytarabine) Prescribing Information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209265s000lbl.pdf

[2] Schiller, G. J., et al. (2017). Efficacy and safety of daunorubicin and cytarabine liposome (CPX-351) in older adults with newly diagnosed high-risk acute myeloid leukemia: results from the phase 3 VIALE-A trial. Blood, 130(Supplement 1), 107. https://ash.confex.com/ash/2017/webprogram/Paper99269.html

[3] Pollyea, D. A., et al. (2018). Randomized trial of Venetoclax Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia. Blood, 132(Supplement 1), 6. https://ash.confex.com/ash/2018/webprogram/Paper115145.html

[4] Jazz Pharmaceuticals. (2022). Jazz Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results. Jazz Pharmaceuticals Investor Relations. Retrieved from https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-results

[5] Jazz Pharmaceuticals. (2024). Jazz Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results. Jazz Pharmaceuticals Investor Relations. Retrieved from https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-results

[6] European Medicines Agency. (2018). Vyxeos Summary of Product Information. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos